Moderna shares opened 13 per cent higher at a record $144 following the results and then went on to hit a peak of $150.14, or a gain of 668 per cent so far this year.
“Although we await the full details of these results in published form, we can now assume that this vaccine will be approved for use in December,” said Gillies O’Bryan-Tear, chair of policy and communications at Britain’s Faculty of Pharmaceutical Medicine. Switzerland’s Lonza, which has a contract with Moderna to supply ingredients for the vaccine, rose 4.4 per cent.
“At this level of effectiveness, when you just do the math of what it means for the pandemic that’s raging around us, it’s just overwhelming,” said Mr Zaks, who said he cried when he saw the final results over the weekend. Soon after getting the green light, Moderna expects its vaccine to be shipped to distribution points across the United States by the government’s Operation Warp Speed program and drug distributor McKesson Corp.
“Whilst this does not exclude some risk of severe disease after vaccination given the relatively small number of severe cases, these results suggest very high efficacy,” she said.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.